Charles Schwab’s Avidity Biosciences RNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $29.8M | Buy |
1,048,219
+24,641
| +2% | +$700K | 0.01% | 1437 |
|
|
2025
Q1 | $30.2M | Sell |
1,023,578
-5,353
| -0.5% | -$158K | 0.01% | 1392 |
|
|
2024
Q4 | $29.9M | Buy |
1,028,931
+38,749
| +4% | +$1.13M | 0.01% | 1458 |
|
|
2024
Q3 | $45.5M | Buy |
990,182
+197,065
| +25% | +$9.05M | 0.01% | 1187 |
|
|
2024
Q2 | $32.4M | Buy |
793,117
+244,682
| +45% | +$10M | 0.01% | 1361 |
|
|
2024
Q1 | $14M | Buy |
548,435
+2,664
| +0.5% | +$68K | ﹤0.01% | 1815 |
|
|
2023
Q4 | $4.94M | Buy |
545,771
+30,674
| +6% | +$278K | ﹤0.01% | 2316 |
|
|
2023
Q3 | $3.29M | Sell |
515,097
-16,546
| -3% | -$106K | ﹤0.01% | 2434 |
|
|
2023
Q2 | $5.9M | Buy |
531,643
+43,046
| +9% | +$477K | ﹤0.01% | 2169 |
|
|
2023
Q1 | $7.5M | Buy |
488,597
+24,779
| +5% | +$380K | ﹤0.01% | 2006 |
|
|
2022
Q4 | $10.3M | Buy |
463,818
+86,700
| +23% | +$1.92M | ﹤0.01% | 1835 |
|
|
2022
Q3 | $6.16M | Buy |
377,118
+39,639
| +12% | +$647K | ﹤0.01% | 2109 |
|
|
2022
Q2 | $4.9M | Buy |
337,479
+37,677
| +13% | +$547K | ﹤0.01% | 2194 |
|
|
2022
Q1 | $5.54M | Buy |
299,802
+8,461
| +3% | +$156K | ﹤0.01% | 2221 |
|
|
2021
Q4 | $6.93M | Buy |
291,341
+7,990
| +3% | +$190K | ﹤0.01% | 2188 |
|
|
2021
Q3 | $6.98M | Buy |
283,351
+140,392
| +98% | +$3.46M | ﹤0.01% | 2214 |
|
|
2021
Q2 | $3.53M | Sell |
142,959
-746
| -0.5% | -$18.4K | ﹤0.01% | 2516 |
|
|
2021
Q1 | $3.14M | Buy |
143,705
+33,902
| +31% | +$740K | ﹤0.01% | 2520 |
|
|
2020
Q4 | $2.8M | Buy |
109,803
+1,935
| +2% | +$49.4K | ﹤0.01% | 2487 |
|
|
2020
Q3 | $3.04M | Buy |
+107,868
| New | +$3.04M | ﹤0.01% | 2319 |
|